| 裴氏兰州方联合重组人血小板生成素治疗阴虚火旺证化疗相关性血小板减少症的临床研究 |
| Clinical Study on Pei"s Lanzhou Prescription Combined with Recombinant Human Thrombopoietin in the Treatment of Chemotherapy-related Thrombocytopenia with Yin Deficiency and Fire Excess Syndrome |
| DOI： |
| 中文关键词: 化疗相关性血小板减少症 裴氏兰州方 重组人血小板生成素 阴虚火旺证 临床疗效 安全性 |
| 英文关键词: Chemotherapy-related thrombocytopenia Pei"s Lanzhou Fang Recombinant human thrombopoietin Yin deficiency fire syndrome Clinical efficacy Security |
| 基金项目:2025年甘肃省中医药科研课题项目[GZKG-2025-94]。 |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 目的 探讨裴氏兰州方联合重组人血小板生成素（recombinant human thrombopoietin, rhTPO）治疗阴虚火旺证化疗相关性血小板减少症（Chemotherapy-induced Thrombocytopenia, CIT）的临床疗效及安全性。方法? 选取本院收治的100例阴虚火旺证CIT患者作为研究对象，采用随机数字表法分为对照组与观察组，每组50例。对照组单纯给予rhTPO治疗，观察组在对照组治疗基础上联合裴氏兰州方治疗。两组疗程均为14d。比较两组临床疗效及不良反应发生情况，治疗前后血小板计数（Platelet，PLT）、血小板恢复相关指标、中医证候积分。结果? 治疗后观察组的临床总有效率98.00%显著高于对照组的86.00%（P＜0.05）。治疗7d、10d、14d后，两组PLT水平均较治疗前显著升高（P＜0.05），且观察组PLT水平显著高于同期对照组（P＜0.05）。治疗后观察组血小板恢复至≥75×10?/L、≥100×10?/L的时间均显著短于对照组（P＜0.05），血小板≤50×10?/L的持续时间显著短于对照组（P＜0.05）。治疗后观察组阴虚火旺证候积分显著低于对照组（P＜0.05）。治疗过程中两组不良反应发生率比较（P＞0.05）。结论? 裴氏兰州方联合重组人血小板生成素治疗阴虚火旺证CIT，可显著提升患者血小板计数，加快血小板恢复速度，有效改善阴虚火旺证候，临床疗效确切，且安全性良好。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy and safety of Pei "s Lanzhou Decoction combined with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy-induced thrombocytopenia (CIT) with yin deficiency and fire hyperactivity syndrome.Methods A total of 100 CIT patients with yin deficiency and fire excess syndrome admitted in our hospital were selected as the research objects.They were divided into control group and observation group by random number table method, with 50 cases in each group.The control group was treated with rhTPO alone, and the observation group was treated with Pei"s Lanzhou prescription on the basis of the control group. The course of treatment in both groups was 14d. The clinical efficacy and adverse reactions, platelet count (PLT), platelet recovery related indicators and TCM syndrome scores before and after treatment were compared between the two groups.Results After treatment, the total clinical effective rate of the observation group was 98.00%, which was significantly higher than 86.00% of the control group (P<0.05). After 7 d, 10 d and 14 d of treatment, the PLT levels of the two groups were significantly higher than those before treatment ( P < 0.05 ), and the PLT level of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the time of platelet recovery to ≥75×109/L and ≥ 100×109/L in the observation group was significantly shorter than that in the control group (P<0.05), and the duration of platelet ≤50×109/L was significantly shorter than that in the control group (P<0.05). After treatment, the score of yin deficiency and fire excess syndrome in the observation group was significantly lower than that in the control group? (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05).Conclusion Pei"s Lanzhou Prescription combined with recombinant human thrombopoietin in the treatment of CIT with Yin deficiency and fire hyperactivity syndrome can significantly increase the platelet count, accelerate the recovery of platelets, and effectively improve the Yin deficiency and fire hyperactivity syndrome. The clinical efficacy is definite and the safety is good. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |